Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

Abstract

Efforts to induce the differentiation of cancer stem cells through treatment with all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silencing of the retinoic acid receptor (RAR)-β. The histone deacetylase inhibitor entinostat is emerging as a promising antitumor agent when added to the standard-of-care treatment for breast cancer. However, the combination of epigenetic, cellular differentiation, and chemotherapeutic approaches against triple-negative breast cancer (TNBC) has not been investigated. In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-β expression. Entinostat and doxorubicin treatment inhibited topoisomerase II-β (TopoII-β) and relieved TopoII-β-mediated transcriptional silencing of RAR-β. Notably, EAD was the most effective combination in inducing differentiation of breast tumor–initiating cells in vivo. Furthermore, gene expression analysis revealed that the epithelium-specific ETS transcription factor-1 (ESE-1 or ELF3), known to regulate proliferation and differentiation, enhanced cell differentiation in response to EAD triple therapy. Finally, we demonstrate that patient-derived metastatic cells also responded to treatment with EAD. Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC. Cancer Res; 76(7); 2013–24. ©2016 AACR.

Document Details

Document Type
Pub Defense Publication
Publication Date
Mar 31, 2016
Source ID
10.1158/0008-5472.can-15-1619

Entities

People

  • Angela Brodie
  • Christina Adams
  • David L. Huso
  • Duojia Pan
  • Helen Sadik
  • Kideok Jin
  • Liangfeng Han
  • Nguyen Nguyen
  • Peter Ordentlich
  • Preethi Korangath
  • Qian Chen
  • Roisin M. Connolly
  • Saraswati Sukumar
  • Soonweng Cho
  • Syed Z. Ali
  • Vanessa F. Merino
  • Vered Stearns
  • Xian C. Zhou
  • Yolanda M.n. Foster
  • Zhe Zhang

Organizations

  • Johns Hopkins School of Medicine
  • Johns Hopkins University
  • United States Department of Defense
  • University of Maryland School of Medicine

Tags

Fields of Study

  • Biology

Readers

  • Infectious Disease/Epidemiology
  • Molecular Biology and Genetics
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech